Stephanie J Nahas (Thomas Jefferson University, Jefferson Headache Center, Philadelphia, PA, USA) kindly took the time to discuss with us pooled findings from phase 3 randomised controlled trials with fremanezumab, an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody treatment, specifically in older patients (≥60 years) with episodic or chronic migraine.
1. How does the clinical phenotype of migraine differ in patients aged 60 and over compared with that in younger patients? (0:05)
2. What are the main unmet needs in the treatment of episodic or chronic migraine in this patient group? (0:57)
3. How extensively has fremanezumab been studied in this patient group? (2:01)
4. What were the efficacy and safety findings of your pooled analysis? (3:00)
5. Among older patients, which are likely to benefit most from fremanezumab and in whom is it contraindicated? (4:46)
Speaker disclosure: Stephanie J Nahas has served on an advisory board, as a speaker, or as a consultant for Allergan, Amgen/Novartis, Biohaven, electroCore, Eli Lilly, Impel, Supernus, Teva Pharmaceuticals, Theranica, and Zosano.
Support: Interview and filming supported by Touch Medical Media.
Filmed at the 6th Congress of the European Academy of Neurology (EAN) and 1st EAN Virtual Congress, May 2020.
Related Videos In Headache Disorders
Peter Goadsby, EAN 2020 – Visual Snow Syndrome
Delighted to interview our valued Editorial Board member Peter Goadsby (King’s College Hospital, London, UK), who shared his expert insights on visual snow syndrome and related updates presented at the 1st Virtual EAN Congress. Questions 1. What are the clinical features and spectrum of severity of visual snow syndrome, and how was it first identified? […]
Uwe Reuter, EAN 2020 – Characteristics of the HER-MES trial in episodic and chronic migraine
Uwe Reuter (Charité Universitätsmedizin Berlin, Germany) talks to us about the first head-to-head randomized, double-blind, double-dummy trial of erenumab and topiramate for the prevention of episodic and chronic migraine (ClinicalTrials.gov Identifier: NCT03828539). Questions 1. What are the unmet needs in the treatment of episodic migraine? (0:05) 2. Could you tell us a little about the […]
Hans-Christoph Diener, EAN 2020 – Chronic Migraine and Medication-Overuse Headache – PROMISE-2
Hans-Christoph Diener (Medical Faculty of the University of Duisburg-Essen, Institute for Medical Informatics, Biometry and Epidemiology, Essen, Germany) talks to us about unmet needs in the treatment of chronic migraine and medication-overuse headache, and shares expert insight on the PROMISE-2 trial, which evaluated the efficacy and safety of eptinezumab, a humanized anti-calcitonin gene-related peptide monoclonal […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!